Clinical outcome of patients with NAFLD
| 2006–2016 | |||||
| Cirrhosis | HCC | Diabetes, n (%) | Hypertension, n (%) | Hyperuricaemia, n (%) | |
| Male (n=506) | 1 | 0 | 64 (12.6) | 191 (37.7) | 72 (14.2) |
| Female (n=190) | 0 | 0 | 22 (11.6) | 85 (44.7) | 43 (22.6) |
| 2007–2016 (outcome of new NAFLD) | ||||||||
| Cirrhosis | HCC | Diabetes | Hypertension | Hyperuricaemia | ||||
| n (%) | P value | n (%) | P value | n (%) | P value | |||
| Male | ||||||||
| NAFLD n=138 | 0 | 0 | 14 (10.1) | 0.028 | 47(34.1) | <0.001 | 34 (24.6) | <0.001 |
| Non-NAFLD n=2786 | 0 | 0 | 157 (5.6) | 259 (9.3) | 284 (10.2) | |||
| Female | ||||||||
| NAFLD n=47 | 0 | 0 | 5 (10.6) | 0.014 | 21 (44.7) | <0.001 | 8 (17) | <0.001 |
| Non-NAFLD n=1761 | 0 | 0 | 54 (3.1) | 324 (18.4) | 84 (4.8) | |||
HCC, hepatocellular carcinoma; NAFLD, non-alcoholic fatty liver disease.